Deep sequencing and predictive modeling as a concept for therapeutic decision-making in oncology;"Deep sequencing" und prädiktive Modellierung als Konzept therapeutischer Entscheidungsfindungen in der Onkologie

Onkologe

Volumn 17, Issue 6, 2011, Pages 477-486

  Lehrach, H ^a   Schafer R ^b   Schlag, P M ^b  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Omics analysis; Oncogenic pathway modeling; Personalized medicine; Targeted therapy; Tumor

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER THERAPY; COMPUTER MODEL; HUMAN; MEDICAL DECISION MAKING; MOLECULAR INTERACTION; ONCOLOGY; PERSONALIZED MEDICINE; PREDICTION; SIGNAL TRANSDUCTION;

EID: 80052564937     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-011-2025-9     Document Type: Article

References (19)

1. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422:198-207. (Pubitemid 36362757)
2. Carr PA, Church GM (2009) Genome engineering. Nat Biotechnol 27:1151-1162.
3. Finco TS, Westwick JK, Norris JL et al (1997) Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272:24113-24116. (Pubitemid 27418602)
4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674.
5. Heidorn SJ, Milagre C, Whittaker S et al (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221.
6. Hudson TJ, Anderson W, Artez A et al (2010) International network of cancer genome projects. Nature 464:993-998.
7. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823-837.
8. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459-465. (Pubitemid 37328850)
9. Massarelli E, Varella-Garcia M, Tang X et al (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896. (Pubitemid 46849563)
10. Meyer M, Rubsamen D, Slany R et al (2009) Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One 4:e7768.
11. Neubauer A, Maharry K, Mrozek K et al (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 26:4603-4609.
12. Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17.
13. Rexer BN, Ghosh R, Arteaga CL (2009) Inhibition of PI3 K and MEK: it is all about combinations and biomarkers. Clin Cancer Res 15:4518-4520.
14. Solit D, Sawyers CL (2010) Drug discovery: How melanomas bypass new therapy. Nature 468:902- 903.
15. Stein U, Walther W, Arlt F et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59-67.
16. Sultan M, Schulz MH, Richard H et al (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321:956-960.
17. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789-799. (Pubitemid 39070849)
18. Weijzen S, Rizzo P, Braid M et al (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8:979-986. (Pubitemid 35033702)
19. Wierling C, Kühn A, Daskalaki A et al (2011) Prediction in the face of uncertainty: a Monte Carlo-based simulation strategy for systems biology of cancer treatment. Mutat Res under review.